Form 4 for PCSA Processa Pharmaceuticals, Inc.
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001567619-22-008012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-04 | 2022-03-31 | PCSA | Islam Khalid | Dir | A - Grant | — | +4,392 | 72.5K | +6% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | A | A | 4,392 | — | 72,486 | D | — | — | (F1) Vesting of time-based restricted shares. (F2) Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in a transaction exempt from Section 16 reporting pursuant to Rule 16a-13. |